Beta-lactam and Beta-lactamase Inhibitors Market Overview

Beta-lactam and beta-lactamase inhibitors are natural, semi-synthetic, or synthetic chemical substances. Bacteria and protozoans are inhibited by them. The global Beta-lactam and Beta-lactamase Inhibitors market is expected to grow at significant rate in the forthcoming years.
 
The market for Beta-lactam and Beta-lactamase Inhibitors is expected to develop due to increased consumption in low and middle-income countries (LMICs) and an increase in the prevalence of infectious disorders. In addition, the market is being bolstered by the development of novel techniques for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections, as well as a high number of clinical trials.
 
On the downside, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitorsand the time taken for the regulatory approval are some reasons that expected to hamper the growth of the market. Besides this, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are anticipated to create significant lucrative opportunities for the market players.

Covid-19 Impact on Beta-lactam and Beta-lactamase Inhibitors Market
 
In addition, the current Beta-lactam and Beta-lactamase Inhibitors Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Beta-lactam and Beta-lactamase Inhibitors Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Beta-lactam and Beta-lactamase Inhibitors Market Segment Overview


Based on the Drug Class, the Cephalosporin segment grasp the major share in the market and is estimated to continue this trend during forecast period. This is mostly due to its broad-spectrum activity and the introduction of next-generation cephalosporins that can combat antimicrobial resistance. In addition, it treats infections caused by a variety of germs. As a result, cephalosporin is in high demand among healthcare practitioners and patients, boosting the global market's growth. According to Disease, the Complicated Intra-Abdominal Infections (cIAI) is the largest segment in the market. This is attributed to the rise in burden of sepsis and rapid increase in mortality rate with greater disease severity across the world.

Beta-lactam and Beta-lactamase Inhibitors Market, By Route Of Administration
·       Oral
·       Intravenous
·       Others

Beta-lactam and Beta-lactamase Inhibitors Market, By Disease
·       Urinary Tract Infection (excluding cUTI)
·       Respiratory Infection
·       Skin Infection
·       Complicated Urinary Tract Infection (cUTI)
·       Complicated Intra-Abdominal Infections (cIAI)
·       Nosocomial Pneumonia
·       Blood Stream Infection
·       Other

Beta-lactam and Beta-lactamase Inhibitors Market, By Drug Class
·       Penicillin
·       Cephalosporin
·       Carbapenem
·       Monobactam
·       Combination

Beta-lactam and Beta-lactamase Inhibitors Regional Overview

Geographically, LAMEA is expected to show the highest growth during the forecast period. This is due to the easy accessibility of beta-lactam and beta-lactamase inhibitors over-the-counter as well as there are no regulation or restrictions on their use in this region. On the other hand, Asia-Pacific is another major region for market. This is because of the increase in consumption of beta-lactam and beta-lactamase inhibitors, easy accessibility of these drugs, and rise in sale of beta-lactam and beta-lactamase inhibitors without prescription.

Beta-lactam and Beta-lactamase Inhibitors Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Beta-lactam and Beta-lactamase Inhibitors Market, Key Players

·       Abbott Laboratories
·       Allergan Plc.
·       F. Hoffmann-La Roche Ltd.
·       GlaxoSmithKline plc
·       Merck & Co. Inc.
·       Mylan N.V.
·       Novartis International AG (Sandoz)
·       Pfizer Inc.
·       Sanofi
·       Teva Pharmaceutical Industries Ltd.